Bryan, Garnier & Co continues aggressive growth story

US investment bank Brocair Partners combines with European growth investment bank Bryan, Garnier & Co

[Paris, New York] — 26 November 2019 – Today, Bryan, Garnier & Co announces that it is joining forces with Brocair Partners.

Brocair Partners will operate under the Bryan, Garnier & Co brand with Managing Partner Gregg Blake joining Bryan, Garnier & Co as a partner focused on healthcare M&A and Brocair’s William Pay as a managing director focused on China and East Asia. Brocair’s team will be fully integrated with Bryan, Garnier & Co’s existing investment banking professionals across its New York, London, Paris, Munich, Stockholm, Oslo, Reykjavik and Palo Alto offices. With a 23 person-strong international healthcare team, Bryan, Garnier & Co’s unmatched European healthcare investment banking business will be augmented with a deeper presence globally.

Brocair has conducted cross-border healthcare M&A transactions in Switzerland, France, Ireland, the UK, Sweden, Germany, India and the US over the past 15 years, and is considered a thought leader in many healthcare subsectors. It recently advised Enköping, Sweden-based Lifco AB (OM:LIFCO B) on its acquisition of certain dental product assets of Physics Forceps, based in Detroit, and advised St. Louis-based Lee Biosolutions on its sale to Medix Biochemica, based in Espoo, Finland.

The combination provides a strong foothold for the firm to expand its leading European Life-Sciences practice in North America and Asia.

Olivier Garnier, Co-founder and Managing Partner of Bryan, Garnier & Co comments: “Bryan, Garnier & Co is an independent partnership that combines highly experienced, entrepreneur-minded investment banking professionals with the services and expertise of a top-tier investment bank. The deep healthcare expertise at Brocair will provide a strong driver to accelerate Bryan, Garnier & Co’s development in the sector.”

“We are very pleased to be teaming up with Bryan, Garnier & Co, to expand our collective footprint” says Gregg Blake, Managing Partner at Brocair Partners. “There are many synergies between our firms with deep coverage in Western Europe and the Nordics, as well as North America and Asia. Joining forces with Bryan, Garnier & Co’s robust healthcare and ECM platform will bring significantly more capabilities to bear for our clients worldwide.”

About Brocair Partners:

Brocair Partners, founded in 2004, provides financial advice to businesses serving the healthcare, wellness, and pharmaceutical industries. Brocair provides mergers & acquisitions, corporate finance, and strategic advisory services to companies worldwide, and has deep expertise in cross-border transactions, with recent completed transactions in Sweden, Finland, Switzerland, France, the UK, Ireland, and India, as well as the United States.

About Bryan, Garnier & Co:

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe.

Brocair Advises COLTENE in Acquisition of KENDA

Brocair Partners, a mergers & acquisitions advisor serving the healthcare industry, advised Swiss dental company COLTENE Holding in its acquisition of Liechtenstein-based KENDA

NEW YORK, NY – January 30, 2018 – Brocair Partners, a mergers & acquisitions advisor serving the healthcare industry, advised COLTENE, a SIX Swiss Exchange-listed developer, manufacturer and seller of dental consumables and small equipment in the areas of restoration, endodontics, prosthetics and treatment auxiliaries, on its acquisition of KENDA AG.

KENDA was established in Liechtenstein in 1977 and is a specialized, internationally active manufacturer of silicone polishing instruments for dentistry applications. KENDA manufactures high-precision rotating polishing instruments for dentistry and dental laboratory applications. Its polishers are available as autoclavable versions for multi-patient use and as single-patient polishers for one-time use.

The transaction size was not disclosed.

KENDA’s business will be integrated into COLTENE’s Rotary Instruments product group, expanding the current offering of diamond and carbide burs. COLTENE is enhancing this product group’s portfolio offering, technology know-how and sales flows through this acquisition.

Brocair has an extensive track record advising companies in the dental industry, including completed projects in dental prosthetics, implantology technology, and dental instruments, and is a frequent visitor to major dental trade shows and conferences.

Gregg Blake, Managing Partner of Brocair, explained, “We introduced KENDA to COLTENE, and there was immediate personal chemistry between the leadership of both companies, whose headquarters were only a short distance apart, in eastern Switzerland and Liechtenstein. This acquisition is an outstanding fit from a corporate culture perspective, as well as a smart business combination. This acquisition will complement COLTENE’s global Rotary Instruments business. Combining KENDA’s dental polisher business with COLTENE’s international marketing and sales infrastructure will create opportunities to grow their businesses together in markets around the world.”

About COLTENE:

COLTENE is an internationally active developer, manufacturer and seller of dental consumables and small equipment in the areas of restoration, endodontics, prosthetics and treatment auxiliaries. COLTENE has state‐of‐the‐art production facilities in the USA, Germany, Brazil and Switzerland as well as own distribution organizations in all major markets including China and India. Dentists and dental labs all around the globe trust COLTENE’s high‐quality products. The registered shares of COLTENE Holding AG (CLTN) are listed on SIX Swiss Exchange. Visit COLTENE online at www.coltene.com.

About KENDA:

KENDA, headquartered in Vaduz in Liechtenstein, was established in 1977 and manufactures high-precision rotating polishing instruments for dentistry and dental laboratory applications. Its polishers are available as autoclavable versions for multi-patient use and as single-patient polishers for one-time use. For more information: www.kenda-dental.com.

About Brocair Partners LLC:

Brocair Partners, founded in 2004, provides financial advice to businesses serving the healthcare, wellness, and pharmaceutical industries. We provide mergers & acquisitions, corporate finance, and strategic advisory services to companies worldwide. This transaction and other Brocair transactions can be found here: www.brocair.com.

Brocair advises Groupe Novasep on its divestiture of TangenX

Brocair Partners LLC, an investment bank serving the healthcare industry, advised Groupe Novasep SAS on the divestiture of its biopharmaceutical manufacturing solutions business TangenX Technology Corporation to Repligen Corporation

NEW YORK, NY – February 13, 2017 – Brocair Partners LLC, an investment banking firm serving the healthcare industry, advised Groupe Novasep SAS, which provides manufacturing solutions for life sciences molecules and fine chemicals, on its divestiture of TangenX Technology Corporation to Repligen Corporation for €37 million.

TangenX Technology Corporation, based in Shrewsbury, MA, produces the single-use Sius™ line of tangential flow filtration (“TFF”) cassettes and hardware used in downstream biopharmaceutical manufacturing processes. Single-use Sius TFF cassettes are used in the filtration of biological drugs and are designed to deliver superior performance to traditional (reusable) TFF cassettes in a cost-competitive format that provides user-ready convenience and flexibility.

Repligen, a NASDAQ-listed life sciences company focused on bioprocessing technology, stated that the acquisition strengthened its position as a leader in single-use bioprocessing technologies and extended its reach into downstream processes, where disposables are increasingly being adopted by biopharmaceutical manufacturers for the convenience, flexibility and cost advantages that they offer.

Gregg Blake, Managing Partner of Brocair, explained, “The process was kept on a tight timeline, and there was substantial strategic interest in TangenX’s technology. In the end the valuation exceeded the sellers’ expectations and was a great endorsement of the past several years of work of the entire management teams at Novasep and TangenX.”

Jean Bléhaut, who led the divestment project for Novasep, said: “I am delighted with the contribution of Brocair Partners to this project. They were able to efficiently jump into a fast track project and were instrumental in entertaining excellent communication between the different stakeholders, which is an essential ingredient in a successful deal recipe.”

Groupe Novasep, based in Lyon, France, is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep’s unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

This transaction and other Brocair transactions can be found here.

About Brocair Partners LLC:

Brocair Partners, founded in 2004, provides financial advice to businesses serving the healthcare, wellness, and pharmaceutical industries. We provide mergers & acquisitions, corporate finance, and strategic advisory services to companies worldwide.

Brocair Advises Briggs Healthcare in Acquisition of SimpleLTC

Brocair Partners LLC, an investment bank serving the healthcare industry, advised Briggs Healthcare in its acquisition of data analytics provider SimpleLTC

NEW YORK, NY – August 23, 2016 – Brocair Partners LLC, an investment banking firm serving the healthcare industry, advised Briggs Healthcare, a leading provider of products and services to the senior care, home care, acute care, physician and retail markets, on its acquisition of SimpleLTC Systems, Inc.

Founded in 2003, SimpleLTC offers software products that help long-term care providers simplify data management and analytics, automate manual processes, and comply with regulatory requirements. Over the past three years, SimpleLTC, based in Richardson, Texas, has launched a suite of new analytics tools allowing providers to use predictive intelligence in order to improve quality measures, reduce rehospitalizations, and optimize reimbursement.

The transaction size was not disclosed.

Briggs Healthcare has a long history of delivering documentation tools which support regulatory compliance and quality outcomes in the long-term care and home care industries. With the addition of SimpleLTC, its customers will have the ability to use the data they collect to gain insight to improve their day to day operations, and provide a higher quality of care.

Gregg Blake, Managing Partner of Brocair, explained, “Briggs has deep experience in the long-term care and home health markets, and its products are the standard of care for documentation of patient encounters. But with greater demands for the measurement of the quality of care, Briggs needed to expand its data analytics offerings to provide additional tools for its customers. This acquisition represents an important transformative step for the firm, allowing Briggs to enter the downstream data utilization space and to provide a more complete package of services to its extensive customer base.”

Bruce Dan, CEO of Briggs Healthcare, remarked “Brocair’s professional and experienced team was instrumental in proactively identifying SimpleLTC as the ideal acquisition for our digital expansion plans. Their industry knowledge and patience was a critical part of the acquisition process of introduction, data collection, and close. We have worked with Gregg and his team for several years and look forward to future M&A successes as well.”

About Briggs Healthcare:

For more than 65 years, Briggs Healthcare has been a leading provider of products and services to the senior care, home care, acute care, physician and retail markets. Headquartered in West Des Moines, IA, Briggs Healthcare serves more than 50,000 customers globally with affiliate operations in Waukegan, Illinois, Moorestown, New Jersey, Waco, Texas, and the United Kingdom. Backed by clinical experience and regulatory knowledge, the company develops and markets products that are designed to improve clinical outcomes and reduce operating costs, including proprietary documentation systems, medical record charting, medical supplies and rehabilitation aids, staff education and resource materials and obstetric products. Visit Briggs online at www.BriggsCorp.com.

About SimpleLTC:

SimpleLTC creates software that simplifies regulatory compliance, reimbursement optimization and quality measurement for long-term care. Specialties include predictive MDS and quality measures analytics, MDS transmission and reporting, and Texas Medicaid reimbursement analytics. More than 2,500 long-term care providers now use SimpleLTC products. For more information: www.simpleltc.com.

About Brocair Partners LLC:

Brocair Partners, founded in 2004, provides financial advice to businesses serving the healthcare, wellness, and pharmaceutical industries. We provide mergers & acquisitions, corporate finance, and strategic advisory services to companies worldwide. This transaction and other Brocair transactions can be found here: www.brocair.com

Brocair Partners quoted in Article on Market Confidence

Strategic buyers currently have the upper hand in competitive auctions

By Anthony Noto

themiddlemarket.com

The stage is set for strategic buyers. Uncertainty over macroeconomic issues may have dimmed the corporate lights on M&A plans in previous years, but 2014 is providing a more promising script. Debt financing is readily available; many corporations boast significant cash on their balance sheets; shareholders are clamoring for more than just share buybacks; and companies are scouring for targets at home and abroad with more immediacy than before. CEOs are viewing the M&A scene with more confidence than they have in a long time.

Ametek (NYSE: AME) provides a good showcase for the trend. The Berwyn, Pennsylvania-based maker of electronic instruments and electromechanical devices has inked five acquisitions in 2014 and expects to do more, says William Eginton, senior vice president of corporate development.

“There is a greater depth of deals that are available now,” Eginton says, adding that 2014 has been especially right for well-positioned companies to scoop up targets.

The numbers back him up. Strategic buyers closed 1,251 middle-market deals valued at $144.4 billion in the first eight months of 2014, up from 1,157 valued at $129.3 billion during the same period in 2013, according to Thomson Reuters.

Across all sectors, strategic buyers are making their way back to the negotiating table. General Mills Inc. (NYSE: GIS), for example, recently acquired Annie’s Inc. for $820 million. The deal marks the latest venture into the organic food space for the Minneapolis-based buyer. The last deal of this type for the company was in 2012, when General Mills purchased Food Should Taste Good, a natural snack- foods company based in Needham Heights, Massachusetts. That year, General Mills also focused overseas. It bought a majority stake of the international business of Yoplait SAS for about $1.2 billion, as well as the Brazilian food company Yoki Alimentos SA, which make snacks, side dishes and other products, for $940 million.

The 2012 acquisition spree helped General Mills get greater access to fast-growing international markets, but like other corporate acquirers, General Mills chose to remain quiet on the M&A front during 2013 – a year many dealmakers predicted would be a boon but turned out to be a bust.

When domestic sales jumped for many companies in 2014, Annie’s became an attractive target. The company, backed by Solera Capital, achieved $204 million in food sales over the last fiscal year.

Berkeley, California-based Annie’s exemplifies the huge shift in consumer demand for healthier foods. Annie’s is known for not using any artificial flavors, synthetic colors or preservatives – the same additives that General Mills is known for using in popular cereal brands and traditional bagged snacks.

The private equity industry has pounced on the good-for-you trend. Now, strategic buyers are more willing to take risks and put money to work.

Strategic buyers are spending more, too. Deal value for transactions helmed by corporations amounted to $144.4 billion for the first eight months of 2014. That’s 11 percent more than the first eight months of 2013, propelling the first half of 2014 to be the best for overall M&A in three years, according to Thomson Reuters.

“The deal flow is higher than it has been in the past several years,” says Eginton, who stepped into his current post in 2004. Before that, he had been overseeing Ametek’s corporate development efforts since 1998.

In 2014, Ametek teed off with the $91.7 million purchase of Luterbach, Switzerland-based Teseq Holding AG. The company, which included 13 affiliates, manufactures test and measurement equipment. Ametek hired Swiss law firm CMS von Erlach Poncet Ltd. to advise on the acquisition process.

A month later, Ametek paid $74 million for VTI Instruments Corp., an Irvine, California-based company that makes testing and measurement instruments for the aerospace and defense sectors.

And in June, Ametek bought Zygo Corp. (Nasdaq: ZIGO) for $372.8 million. The Middlefield, Connecticut, company provides optical metrology services and products for the defense, semiconductor and life-sciences markets.

August also proved to be busy. Ametek acquired two companies: Luphos GmbH in Mainz, Germany, and Amptek Inc. in Bedford, Massachusetts. Luphos was a technology play that Ametek expects will expand the company’s access to innovations in measuring optical surfaces. Amptek is a provider of sensor and detector technology used in the metal, environmental monitoring, petrochemical and semiconductor markets. Terms of each deal remain undisclosed, but Eginton reports that the price tags on companies that are up for sale are rising.

“Bankers are busier,” Eginton adds. “Also, we have a tremendous team that’s able to recognize trends.”

One trend propelling the company forward is the fact that companies with a manufacturing component are more in demand.

As companies work to meet development needs, and get products to local markets at a quicker pace, they are opting to grow via M&A as opposed to bolstering in-house research and development departments, says Daniel Meckstroth, chief economist at the Manufacturers Alliance for Productivity and Innovation, a research organization in Arlington, Virginia.

Merck KGaA (ETR: MRK), based in Darmstadt, Germany, provides a good example. In September,Merck agreed to buy Sigma-Aldrich Corp. (Nasdaq: SIAL) for $17 billion in cash to expand in chemicals used in research labs and pharmaceutical manufacturing. The purchase, announced just months after the May close of Merck’s $2.5 billion acquisition of chemical supplier AZ Electronic Materials SA, serves as a way to boost Merck’s growth and reduce dependence on researching biotechnology developments within its own subsidiary, Serono. Before AZ, the Germany-based company last announced a major acquisition in 2010, when it acquired Millipore Corp., a U.S. maker of lab equipment and chemicals, for about $6 billion.

“Corporations have the cash to do deals and spend,” Meckstroth says. “They don’t have to borrow it; they can finance it internally and they’re much more willing to take risks.”

With the general economic outlook relatively stable, executives are more willing to pursue acquisitions they have long considered.

“How do you achieve superior growth? You get it through mergers and acquisitions, because you’re essentially buying sales,” Meckstroth says.

Fueling these deals is the fact that companies are more willing to sell at the valuations they are at today.

That has helped foster a different tone in 2014, says Ulderico Conte, former chief executive of self-serve yogurt franchiser U-Swirl Inc. Conte, who led three acquisitions in 2014 for Henderson, Nevada-based U-Swirl, explained that strategic transactions are now coming to fruition based on prior plans. From 14 stores in 2011 when it was founded, the company wielded M&A to expand to roughly 298 self-serve frozen yogurt cafés in 37 states and four non-U.S. countries.

U-Swirl is majority-owned by Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF), which acquired a 60 percent equity interest in the company in January 2013. At the time, the company set out to scoop up rival self-serve yogurt franchises and made good on its plan.

In 2014, U-Swirl has spent a total of $10 million on three rival companies: CherryBerry Enterprises LLC, Yogli Mogli Franchise LLC and Fuzzy Peach Franchising LLC. Tulsa, Oklahoma-based CherryBerry and Atlanta-based Yogli Mogli were both bought in January, followed by Wilmington, North Carolina-based Fuzzy Peach in February.

“Market conditions have played a factor,” Conte says on the trio of purchases. “We were finally able to get strategic.”

Investment bankers agree.

“Deals are getting completed this year even though a strategy was set last year,” says Gregg Blake, managing partner of advisory firm Brocair Partners. “Valuations are also substantially higher than they were before.”

The high prices aren’t intimidating strategic buyers, who are able to write bigger checks. As a result, targets now find themselves in a position to be pickier with suitors, or hike up already-high terms.

Take the competition for Family Dollar Stores Inc. Dollar General Corp. was spurned twice in its attempts to buy Family Dollar. Then the company tried a hostile bid, bringing a whopping $9.1 billion offer directly to shareholders. But Family Dollar has accepted a lower bid from DollarTree Inc. instead, saying that deal is more likely to gain regulatory clearance with antitrust authorities. A merger with Dollar General would create a massive retail chain with almost 20,000 locations, putting it in direct competition with Wal-Mart Stores Inc., the largest retail chain, which has been pushing deeper into the market for neighborhood discount stores.

In other cases, strategic buyers are competing with private equity firms, which have been fairly consistent when it comes to deal flow, just as much as they have been in previous years. In fact, in 2009, private equity firms disbursed more capital to U.S. firms than the previous year, and they’ve done the same in every year since, according to Thomson Reuters. From the looks of it, 2014 is on track to surpass previous years. That was not the case with strategic buyers-until now.

While corporate acquirers take the field, some private equity firms may feel benched as strategic capital tends to be cheaper than private equity capital, leaving sponsors at a competitive disadvantage. This is evident in many auction situations, says Brocair’s Blake, who advised UDG Healthcare plc, a Dublin-based provider of health care services, on its successful bid for the health care communications business of KnowledgePoint 360 LLC. UDG beat several PE firms to acquire the Lyndhurst, New Jersey-based target, which was sold by PE firm Abry Partners LLC.

“Borrowing costs are low and financing is so cheap that it makes strategic buyers able to outbid PE funds for the same assets,” Blake adds. “Sometimes strategic companies are outbid by PE funds, but right now it’s the other way around. If you’re a big enough company, you can theoretically finance an acquisition entirely with debt. PE funds can’t do that. If they’re doing an add-on acquisition they might be able to, but they traditionally have to use a certain amount of equity, especially for a new platform.”

As the crucial fourth quarter rolls out, the strategic hits are likely to keep on coming. Don’t be surprised to see some big deals before the year is over. Megamergers, deals of more than $20 billion, have hit a record $788 billion in 2014. The tech sector seems especially ripe. In September, China’s Alibaba Group Holding Ltd. (NYSE: BABA) raised $21.8 billion in the largest tech initial public offering ever. Led by CEO Jack Ma, now the richest person in China, Alibaba has already spent $4.6 billion in acquisitions in 2014. Some speculate that the e-commerce giant may try to buy Yahoo Inc. (Nasdaq: YHOO), which holds 16 percent of Alibaba. Another potential bidder for Yahoo is Japanese telecommunications company SoftBank. Led by CEO Masayoshi Son, the second-richest person in Japan, SoftBank retains 32 percent of Alibaba.

Strategic buyers may make hay only when the sun shines, but the sun doesn’t seem likely to set any time soon.

Brocair advised on $144 million acquisition of the medical communications business of KnowledgePoint360 by UDG Healthcare

Brocair Partners LLC, an investment bank serving the healthcare industry, advised on the acquisition of the US and UK-based healthcare communications business of KnowledgePoint360 by Ireland-based UDG Healthcare

NEW YORK, NY – March 20, 2014 – Brocair Partners LLC, an investment banking firm serving the healthcare industry, advised UDG Healthcare plc, a London Stock Exchange-listed leading international provider of services to healthcare manufacturers and pharmacies based in Dublin, Ireland, on its acquisition of the healthcare communications business of KnowledgePoint360. KnowledgePoint360 is based in Macclesfield, United Kingdom, and Lyndhurst, New Jersey, and was a portfolio company of ABRY Partners, based in Boston, Massachusetts.

The deal, agreed at a total cash consideration of $144 million [€105 million], is expected to complete by the end of March 2014.

The acquisition establishes UDG Healthcare as a leader in the global healthcare communications market, complementing UDG Healthcare’s existing global healthcare communications offering, which it provides through its Ashfield Division in the UK and the US.

Gregg Blake, Managing Partner of Brocair, explained, “UDG has been a long-standing client of Brocair, and we have evaluated a range of opportunities for strategic investment over the years. The transaction represents the largest acquisition to date in UDG’s history, and will position UDG’s Ashfield Division as the leading provider of healthcare communications services worldwide, with a very strong market position in Europe and North America.”

Liam Logue, Director of Group Corporate Development at UDG Healthcare, remarked “Gregg and the rest of the Brocair team were exceptionally professional and responsive throughout the transaction process. Their efforts were critical in helping us refine our approach and work through the complexities that always emerge during the negotiation process. We were very pleased with Brocair’s contribution to the transaction.”

UDG Healthcare plc is a leading international provider of services to healthcare manufacturers and pharmacies, with operations in 22 countries including the US, UK, Ireland and Germany. The Group operates across three divisions: Ashfield Commercial and Medical Services, Supply Chain Services and Sharp Packaging Services.

Ashfield Commercial and Medical Services is a global leader in the provision of contract sales outsourcing services to pharmaceutical manufacturers, with operations in major markets including continental Europe, the UK, North America and a presence in South America and Asia. The division provides sales teams, telesales, nurse educators, medical information, healthcare communications and event management services to healthcare companies in 22 countries. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle.

KnowledgePoint360 is a leading global provider of multi-channel healthcare communication services. It employs over 600 staff across 10 global locations. KnowledgePoint360 is principally a healthcare communications business, including medical education, publication support, thought leader engagement and scientific content development, with a complementary meetings management division. These services are normally sold to global pharmaceutical companies across the medicines life cycle but, in particular, at the pre-launch stage, to educate key influencers about the therapeutic category and the relevant products being brought to market.

Brocair Partners LLC, with its headquarters in New York, provides investment banking services to businesses serving the healthcare, wellness, and pharmaceutical industries. Brocair provides mergers & acquisitions, corporate finance, and strategic advisory services to companies worldwide.

Brocair Managing Partner Participates in Healthcare Panel

Gregg Blake Offers Insight During Capital Forum with Cold Spring Harbor Laboratory

Melville, NY – June 20, 2013 – The Long Island Capital Alliance (“LICA”), the leading non-profit capital formation and business development organization serving regional companies, today announced the successful completion of its Biotech Technology Transfer Capital Forum held on June 14, 2013. The capital forum, held in collaboration with Cold Spring Harbor Laboratory (“CSHL”), showcased four scientific discoveries which can form the basis for new businesses which are based on technologies developed by CSHL scientists.

A panel of technology investors also participated in the event. The panel provided insights on the presenting scientists’ business plans and their investment potential, as well as a review of the current investment climate for technology transfer within the biotechnology sector.

Neil Kaufman, chairman of LICA, stated that, “We are extremely excited to have showcased some of the most advanced biotechnology discoveries made at CSHL which are ready for transfer to the commercial marketplace. A large number of investors and local business leaders turned out to hear about these insightful technology transfer concepts from CSHL, including the treatment of diabetes, obesity and cancer, enhanced drug development and research tools and healthcare products. CSHL is clearly shaping contemporary biomedical research and we are pleased to have been able to collaborate in bringing their technologies toward monetization in a way that is intended to create locally-based companies.”

“The LI Capital Forum meeting was well attended by a cross section of experienced, knowledgeable and interested professionals. The Q&A panel was particularly experienced and helpful to all involved,” said John Maroney, Vice President, In-House Counsel at Cold Spring Harbor Laboratory (CSHL). “As a global leader in biomedical research, CSHL is interested in pursuing technology transfer opportunities that will bring our scientific expertise into commercial application and our scientist entrepreneurs who participated benefitted from the interaction.”

“The forum presented a unique opportunity to connect with the investment community and we found there to be a lot of interest as we implement our strategy for commercialization as a profitable business from our present status as an advanced stage not-for-profit entity,” said Professor Lloyd Trotman, a CSHL presenter.

Professor Nicholas Tonks of CSHL commented, “I found the forum to be very helpful – it provided important insights into how best to communicate scientific breakthroughs to the business community. The feedback from the panel regarding what they viewed as important attributes of early stage companies was valuable. The opportunity to present our work and to meet members of the business community also helped to make potentially productive connections.”

“I was fascinated by all three presenters and I’m looking forward to following up to determine our role in funding their commercialization,” said Scott Livingston, President of Livingston Securities, a leading investment bank focusing on disruptive technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy.

Biotech Technology Transfer Capital Forum
Presenting Companies and Technologies

The following presentations were given at the Capital Forum:

A Novel Treatment for Diabetes, Obesity and Cancer: exploiting an oral dosage of a key regulator of insulin, leptin and HER2 oncogene function. (Professor Nicholas Tonks, FRS)

RapidCaP: the next generation platform to cure metastatic prostate cancer. (Professor Lloyd Trotman)

Velocin-N™: a new enzyme that enables faster, more sensitive and more selective detection of proteins (the miniature machines and structures of life) in mass spectrometers. (Dr. John Wilson)

Wilson Advanced Research: develops products with novel health, social and commercial benefit, spanning a wide range from consumer products to environmental clean-up, including a simple solution to eliminate the largest reservoir of bacteria–including MURSA and E. coli 0157– from homes. (Dr. John Wilson)

Biotech Technology Transfer Capital Forum
Industry Experts

The following industry investors participated in the panel discussion at the Capital Forum:

Gregg Blake, Founder of Brocair Partners, which provides financial and strategic advisory services to healthcare companies.
•Larry Chaityn, Managing Director and Head of Global Health Care Banking at Kaminski Partners, a global investment bank.
•Scott Livingston, President of Livingston Securities, an investment bank specializing in the nanotechnology and biosciences industries.
•Steve Winick, Principal of Topspin Partners, one of Long Island’s leading venture capital firms.

About the Long Island Capital Alliance:

Since 1984, the Long Island Capital Alliance (www.licapital.org), formerly known as Long Island Venture Group, has been promoting business growth on Long Island. LICA seeks to create a productive and business-friendly environment that will afford area businesses access to the resources necessary to compete successfully in today’s markets. LICA serves as a focal point for the exchange of ideas among new and existing business enterprises, successful entrepreneurs, investors, and service providers. Through quarterly capital forums and special meetings, LICA brings together members of the region’s business community, and has been recognized as the place to turn to when small businesses need equity, debt, or other financing, or for investors to find an attractive investment opportunity.

LICA’s mission is to encourage economic development on Long Island by facilitating capital formation for a broad range of companies in various industries, from early stage to mature middle market closely held and publicly-traded businesses. LICA accomplishes this primarily through education, networking, quarterly capital forums, periodic special educational meetings, and alliances with other regional organizations. LICA brings together members of the region’s business community and serves as the finance arm for significant local business and organizations.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL’s multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory’s education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.

Brocair Partners quoted in Article on Latin American OTC Deal

Reckitt Benckiser, Bristol-Myers sign $482M pact

New York biopharmaceutical company Bristol-Myers Squibb Co. announced Tuesday, Feb. 12, that it struck a collaboration agreement with Slough, U.K., healthcare and consumer products business Reckitt Benckiser Group plc worth $482 million.

By Thomas Zadvydas

TheDeal.com

February 12th, 2013 – Terms of the deal state that Reckitt Benckiser will pay Bristol-Myers $438 million up front for the exclusive rights to sell, distribute and market seven medicines primarily sold in Latin America for a three-year period.

The compounds are Picot, an antacid; Tempra, a pain reliever and fever reducer; Micostatin, an antifungal treatment; Graneodin, a cough and cold medicine sold primarily in Mexico; Dermodex, an anti-rash cream; Luftal, an anti-gas medicine; and Naldecon, a cold and flu symptoms treatment, sold mainly in Brazil.

“[The deal] increases our consumer healthcare capability in Latin America,” Reckitt Benckiser senior vice president Andraea Dawson-Shepherd said. “It’s a good set of brands.”

The assets had net revenue for the year ended Dec. 31 of $102 million, Reckitt said.

Bristol-Myers will retain responsibility for manufacturing all of the products covered by the collaboration during its terms. Reckitt Benckiser will purchase products from Bristol-Myers and pay royalties on product sales.

The deal also includes a $44 million payment of an option fee by Reckitt Benckiser to Bristol-Myers for the right to purchase the medicines outright at the end of the three-year term. The final purchase price would be based on average net sales during the two-year period before the closing of the acquisition. No manufacturing facilities will be transferred as part of the deal.

One banker sees the deal as a bet on the expanding middle class in the region with larger disposable incomes.

“Latin America is an [expanding] healthcare market,” said managing partner Gregg Blake of healthcare boutique Brocair Partners. “If you take Brazil for instance, a lot of people over the last 10 years have moved up into the wealthier economic classes.” Blake estimates the healthcare market in Brazil to stand at about $209 billion and the market in Mexico to be worth about $65 billion.

“And it’s growing,” he added.

Reports surfaced in January that Bristol-Myers was seeking a buyer for some of its brands in Mexico and Brazil worth as much as $750 million. The transaction is subject to customary closing conditions, including competition law clearance by authorities in Brazil and Mexico.

“Bristol-Myers Squibb has worked to focus its businesses around the world on innovative medicines in areas of high unmet medical need,” CFO Charles Bancroft said in a statement Tuesday.

Kevin Sheridan, Abid Rizvi and Dung Nguyen at Jefferies & Co. advised Bristol-Myers on the deal. David Fox, Daniel Wolf and Joshua Zachariah at Kirkland & Ellis LLP were legal counsel. Simon Smith, Siddhart Nahata, Susan Huang and Pedro Costa at Morgan Stanley advised Reckitt Benckiser, while Toby Myerson, Steven Williams, Chuck Googe and Andrew Gaines at Rifkind, Wharton & Garrison LLP were legal counsel.

Bristol-Myers didn’t return calls Tuesday.

Bristol-Myers shares fell 31 cents, or 0.84%, to $36.62, on Tuesday afternoon. Reckitt Benckiser shares closed up 27.16 pence, or 0.64%, to 4,262.16 pence, Tuesday afternoon in London.

Brocair advises Biomain AB in sale to Heraeus Group

Brocair Partners LLC, an investment bank serving the healthcare industry, advised Biomain AB in its sale to Heraeus Group

NEW YORK, NY – March 5, 2012 – Brocair Partners LLC, an investment banking firm serving the healthcare industry, in conjunction with Experia Corporate Finance Advisors AB, based in Stockholm, advised Biomain AB, a Helsingborg, Sweden-based dental prosthetics company, on their sale to Heraeus Dental, part of the Heraeus Group, a precious metals and technology holding company based in Hanau, Germany.

The acquisition strengthens Heraeus’ presence in the Northern European dental market and expands its patent and product portfolio in digital implant prosthetics.

Gregg Blake, Managing Partner of Brocair, explained, “Biomain had a set of products and intellectual property that had enabled them to attain a dominant position in the Nordics in the CAD/CAM dental prosthetics space. This is a rapidly growing market, and we found there was strong demand from major dental industry players with a strategic interest in the field. The valuation reflected the competitive nature of the process and the high level of strategic interest.”

Anders Williamsson, Chairman of Biomain, remarked “As Chairman of the business, I was impressed with the speed and quality of the investment banking effort, and the transaction value was an exceptional endorsement of the quality of the business. The Board and owners were extremely pleased with the whole process, and the outcome was a classic win-win situation for both the company and the buyer.”

Håkan Persson, Managing Partner of Experia, commented “This demonstrates again the virtues of a transatlantic advisory team with members from both Brocair and Experia. With professionals covering our different geographies and time zones, we could market the opportunity to all relevant parties, creating the competitive selling process that was the key to the successful outcome for our client.”

Mr. Blake summarized, “The transaction was an excellent fit for both parties—Biomain has the advantage of being part of a larger platform, and Heraeus has an opportunity to expand its product range and market share in Northern Europe.”

The purchase price was not disclosed, but Swedish press reports indicate the valuation was in excess of SEK 200 million.

Founded in 2002, Biomain AB, based in Helsingborg, Sweden, is the Scandinavian market leader in the field of custom CAD/CAM-produced implant prosthetics and has a workforce of 40 employees.

Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Its fields of competence include precious metals, materials and technologies; sensors; biomaterials; and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metals trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.

Outpatient Rehabilitation Market, July 2011

The rehabilitation therapy industry in the U.S. consists of about 30,000 establishments with combined annual revenues of approximately $20 billion. The industry is highly fragmented, with the top 50 companies accounting for less than 25% of total revenue.

More specifically, the outpatient rehabilitation industry accounts for nearly $5 billion of Medicare spending in the U.S. This figure has been rising steadily, and has more than doubled since 2000.

The three primary classifications within outpatient rehabilitation are physical therapy, occupational therapy, and speech language pathology.

Read More >